CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
AL English
Country • Albania
    Entity • Capital Com Online Investments Ltd (SCB) (Regulated by SCB)
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade FibroGen, Inc - FGEN CFD

    0.33
    0%
    • Summary
    • Historical Data
    Trading сonditions
    Spread 0.04
    Long position overnight fee

    Long position overnight funding adjustment

    Margin. Your investment $1,000.00
    Overnight funding adjustment -0.024346 %
    Charges from full value of position ($-0.24)
    Trade size with leverage ~ $2,000.00
    Money from leverage ~ $1,000.00
    Go to platform
    		-0.024346%
    Short position overnight fee

    Short position overnight funding adjustment

    Margin. Your investment $1,000.00
    Overnight funding adjustment 0.002124 %
    Charges from full value of position ($0.02)
    Trade size with leverage ~ $2,000.00
    Money from leverage ~ $1,000.00
    Go to platform
    		0.002124%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 50.00%
    Stock exchange United States of America
    Commission on trade 0%

    Key Stats
    Prev. Close 0.33
    Open 0.33
    1-Year Change -50%
    Day's Range 0.33 - 0.33
    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 17, 2024 0.33 0.00 0.00% 0.33 0.33 0.32
    Dec 13, 2024 0.32 0.00 0.00% 0.32 0.32 0.32
    Dec 12, 2024 0.34 0.00 0.00% 0.34 0.34 0.34
    Dec 11, 2024 0.34 0.00 0.00% 0.34 0.34 0.34
    Dec 10, 2024 0.33 0.00 0.00% 0.33 0.35 0.32
    Dec 9, 2024 0.34 0.01 3.03% 0.33 0.34 0.33
    Dec 6, 2024 0.31 -0.06 -16.22% 0.37 0.38 0.31
    Dec 5, 2024 0.38 0.00 0.00% 0.38 0.39 0.38
    Dec 4, 2024 0.37 0.00 0.00% 0.37 0.38 0.37
    Dec 3, 2024 0.39 0.00 0.00% 0.39 0.39 0.38
    Dec 2, 2024 0.40 0.01 2.56% 0.39 0.40 0.34
    Nov 29, 2024 0.41 0.01 2.50% 0.40 0.41 0.40
    Nov 27, 2024 0.36 -0.01 -2.70% 0.37 0.37 0.36
    Nov 26, 2024 0.37 0.00 0.00% 0.37 0.37 0.37
    Nov 25, 2024 0.38 0.02 5.56% 0.36 0.38 0.36
    Nov 22, 2024 0.36 -0.01 -2.70% 0.37 0.37 0.36
    Nov 21, 2024 0.35 0.03 9.37% 0.32 0.35 0.32
    Nov 19, 2024 0.32 -0.01 -3.03% 0.33 0.33 0.32
    Nov 15, 2024 0.34 0.00 0.00% 0.34 0.34 0.34
    Nov 14, 2024 0.36 0.01 2.86% 0.35 0.36 0.34

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    • 2:1
    Leverage
    2:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    FibroGen, Inc Company profile

    About FibroGen Inc

    FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.

    Industry: Biotechnology & Medical Research (NEC)

    409 Illinois Street
    SAN FRANCISCO
    CALIFORNIA 94158
    US

    News

    Pi Network coin price prediction: Third party price target

    Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com

    13:51, 13 December 2024
    Two €50 banknotes on a map of Europe

    Euro forecast: third party data roundup

    In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.

    22:39, 12 December 2024
    Financial data on the monitor

    Projected US interest rates in 5 years: Third party round up

    As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?

    14:28, 12 December 2024
    Street in City of London with Royal Exchange, Bank of England and new modern skyscrapers

    Projected UK interest rates in 5 years

    Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?

    11:20, 12 December 2024
    Dogecoin token on mobile phone screen

    Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target

    We look at the meme coin’s price performance and the latest DOGE price predictions

    08:37, 12 December 2024
    Gold bars on a black background with a diagram

    Gold price predictions for the next five years: Third party data round up

    Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.

    09:13, 6 December 2024
    Rendering of physical bitcoin tokens on black background

    Bitcoin price predictions 2025–2050: third-party price target

    We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.

    12:47, 5 December 2024

    People also watch

    US100

    22,000.70 Price
    +0.160% 1D Chg, %
    Long position overnight fee -0.0243%
    Short position overnight fee 0.0021%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    BTC/USD

    104,103.90 Price
    -1.970% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 50.00

    XRP/USD

    2.48 Price
    -5.310% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 0.01235

    ETH/USD

    3,860.12 Price
    -1.840% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 1.75

    Still looking for a broker you can trust?

    Join the 660,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading